Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan and Azenosertib in HER2-Expressing Solid Tumors
NCT06364410Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azenosertib in gastric cancer (GC), gastroesophageal junction adenocarcinoma and solid tumor (3 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 2 more. Started Feb 2025; status: recruiting.
02
Drugs
azenosertib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomasolid tumor
Beyond the preview
Go deeper on NCT06364410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364410.